News|Articles|November 15, 2026

FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC

Author(s)Jonah Feldman
Fact checked by: Jason M. Broderick
Listen
0:00 / 0:00

Key Takeaways

  • FDA concluded that PFS benefit without statistically significant OS improvement did not support a favorable benefit–risk profile for approval in EGFR TKI–resistant EGFRm NSCLC.
  • HARMONi demonstrated median PFS 6.8 vs 4.4 months (HR 0.52; P<.0001) with higher ORR and longer DOR for ivonescimab plus carboplatin/pemetrexed.
SHOW MORE

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

The FDA has issued a complete response letter (CRL) for the biologics license application (BLA) seeking approval of ivonescimab, a PD-1 x VEGF bispecific antibody, in combination with platinum-based chemotherapy for patients with EGFR-mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) whose disease progressed after EGFR tyrosine kinase inhibitor (TKI) therapy.¹

According to Summit Therapeutics, the FDA determined that substantial evidence of effectiveness was not established in the absence of a statistically significant overall survival (OS) improvement. The agency indicated that the progression-free survival (PFS) benefit, without a statistically significant OS benefit, does not support a positive benefit-risk profile for approval.

The BLA was based on results from the global phase 3 HARMONi trial (NCT06396065), in which adding ivonescimab to carboplatin and pemetrexed improved PFS compared with placebo plus carboplatin/pemetrexed in patients previously treated with a third-generation EGFR TKI. Median PFS by independent review was 6.8 months with the ivonescimab combination vs 4.4 months with chemotherapy alone (HR, 0.52; 95% CI, 0.41-0.66; P < .0001).²˒³ However, the OS difference at the primary analysis did not reach statistical significance.

"We are disappointed for patients and their families awaiting additional treatment options in this setting," Robert W. Duggan, chairman and co-chief executive officer of Summit, said in the press release. "We chose to pursue an ivonescimab regimen here based on the opportunity to provide another treatment option to help patients in need. In doing so, we believe the global HARMONi study provided the basis for a treatment option that these patients needed."

Summit noted that no FDA-approved regimens have demonstrated a statistically significant OS benefit in this setting. Ivonescimab remains investigational in the United States and Europe, and no PD-1 x VEGF bispecific antibodies are currently approved in the United States.

HARMONi Trial Design

Ivonescimab is a bispecific antibody that binds PD-1 and VEGF in a single tetravalent molecule. The randomized, double-blind HARMONi trial enrolled 438 adults at 114 centers in North America, Europe, and Asia. Eligible patients had unresectable locally advanced or metastatic nonsquamous NSCLC with an EGFR sensitizing mutation that had progressed on a third-generation EGFR TKI and an ECOG performance status of 0 or 1; patients were eligible regardless of PD-L1 expression. Patients were randomly assigned 1:1 to ivonescimab 20 mg/kg or placebo, each given with carboplatin (AUC 5) and pemetrexed (500 mg/m²) every 3 weeks for 4 cycles, followed by pemetrexed for up to 2 years. The primary end points were PFS and OS.

HARMONi Efficacy Findings

Results from HARMONi were presented at the 2025 World Conference on Lung Cancer by Jonathan Goldman, MD, of UCLA, and published in The Lancet Oncology. At a median follow-up of 22.3 months for PFS, the 6- and 12-month PFS rates were 54.0% and 25.4% with ivonescimab vs 34.7% and 8.3% with placebo, respectively. The objective response rate was 45% vs 34%, and the median duration of response was 7.6 months vs 4.2 months.

At the primary analysis, median OS was 16.8 months with the ivonescimab regimen and 14.0 months with chemotherapy alone (HR, 0.79; 95% CI, 0.62-1.01; P = .057), a difference that did not reach statistical significance.

An updated, post hoc OS analysis announced in July 2026 and presented at the 2026 World Conference on Lung Cancer extended the follow-up for the 165 patients enrolled in North America and Europe (Western cohort) to a June 2026 cutoff.⁴ With a median follow-up of 29.9 months in the overall population, median OS remained 16.8 vs 14.0 months (HR, 0.76; 95% CI, 0.61-0.95; nominal P = .0151). In the Western cohort, median follow-up was 23.2 months, and median OS was 17.5 vs 14.0 months (HR, 0.76; 95% CI, 0.52-1.10).

HARMONi Safety Findings

At the primary analysis, treatment-related adverse events (TRAEs) occurred in 95.0% of patients receiving ivonescimab and 93.1% of those receiving placebo. Grade 3 or higher adverse events occurred in 50.0% vs 42.2% of patients, and serious adverse events in 28.0% vs 15.1%. TRAEs led to discontinuation in 7.3% vs 5.0% of patients and to death in 1.8% vs 2.3%.

The most common TRAEs with ivonescimab were anemia (49.1%), decreased white blood cell count (45.0%), decreased neutrophil count (42.7%), and decreased platelet count (32.6%). Grade 3 or higher immune-related adverse events occurred in 9.6% vs 6.0% of patients, and grade 3 or higher VEGF-related TRAEs in 7.3% vs 3.2%. Hemorrhage occurred in 10.6% of patients receiving ivonescimab, with grade 3 or higher events in 0.9%. Proteinuria (13.8%) and hypertension (13.3%) were the most common VEGF-related events.

In the updated safety analysis, grade 3 or higher TRAEs occurred in 51.4% of patients receiving ivonescimab and 43.6% of those receiving placebo, and grade 3 or higher serious TRAEs in 23.4% vs 14.2%. TRAEs led to discontinuation of ivonescimab or placebo in 9.2% vs 6.4% of patients and to death in 1.8% vs 2.8%. The investigators reported that the safety profile was consistent with the primary analysis.

Completed and Ongoing Studies of Ivonescimab

A separate phase 3 trial conducted in China, HARMONi-A (NCT05184712), showed a statistically significant OS benefit with ivonescimab plus chemotherapy in a similar population, leading to its approval in China in May 2024.⁵

Ivonescimab has been evaluated or is being evaluated in 14 phase 3 trials, 10 of which are based in China and 4 of which are global trials. In the China-based HARMONi-2 trial (NCT05499390), ivonescimab extended survival vs pembrolizumab (Keytruda) in first-line metastatic PD-L1–positive NSCLC, and in the China-based HARMONi-GI1 trial (NCT06591520), it demonstrated superior OS vs durvalumab (Imfinzi) when added to chemotherapy in advanced biliary tract cancer. The global phase 3 HARMONi-3 (NCT05899608) is evaluating ivonescimab in first-line metastatic squamous or nonsquamous NSCLC regardless of PD-L1 expression.

"With five positive Phase III studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab's development," Duggan said.

REFERENCES
1. Summit Therapeutics provides update regarding ivonescimab biologics license application. News release. Summit Therapeutics Inc. November 15, 2026. Accessed November 15, 2026. https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
2. Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026;27(9):1094-1109. doi:10.1016/S1470-2045(26)00282-2
3. Goldman JW, Passaro A, Laskin J, et al. Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. Presented at: International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 4808.
4. Passaro A, Goldman J, Laskin J, et al. Ivonescimab-chemo vs placebo-chemo in EGFR-TKI-resistant, EGFR-mutated NSCLC (HARMONi): updated overall survival analysis. Presented at: IASLC 2026 World Conference on Lung Cancer; 2026; Seoul, South Korea. Abstract OA14.05.
5. Ivonescimab in combination with chemotherapy approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A clinical trial: positive trend observed in overall survival towards ivonescimab plus chemotherapy. News release. Akeso, Inc. June 1, 2024. Accessed November 2, 2026. https://tinyurl.com/2dnjdjxz


Related to this article